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Abstract
DNA microarray technology has led to an explosion of
oncogenomic analyses, generating a wealth of data
and uncovering the complex gene expression patterns
of cancer. Unfortunately, due to the lack of a unifying
bioinformatic resource, the majority of these data sit
stagnant and disjointed following publication, mas-
sively underutilized by the cancer research commun-
ity. Here, we present ONCOMINE, a cancer microarray
database and web-based data-mining platform aimed
at facilitating discovery from genome-wide expression
analyses. To date, ONCOMINE contains 65 gene
expression datasets comprising nearly 48 million gene
expression measurements form over 4700 microarray
experiments. Differential expression analyses compar-
ing most major types of cancer with respective normal
tissues as well as a variety of cancer subtypes and
clinical-based and pathology-based analyses are
available for exploration. Data can be queried and
visualized for a selected gene across all analyses or
for multiple genes in a selected analysis. Furthermore,
gene sets can be limited to clinically important
annotations including secreted, kinase, membrane,
and known gene–drug target pairs to facilitate the
discovery of novel biomarkers and therapeutic targets.
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Introduction
Gene expression profiling with DNA microarrays has
emerged as a powerful approach to study the cancer
transcriptome. More than 100 published studies have
presented analyses of human cancer samples, identifying
gene expression signatures for most major cancer types
and subtypes, and uncovering gene expression patterns
that correlate with various characteristics of tumors in-
cluding tumor grade or differentiation state, metastatic
potential, and patient survival [1–24]. Also, novel tissue
[25,26] and serum [27,28] biomarkers as well as potential
therapeutic targets [29,30] have been identified using these
genome-wide screens. These discoveries highlight the re-
markable impact that DNA microarrays have had on cancer
research; however, we argue that due to limitations of data
availability and integration, the full potential of gene expres-
sion profiling with microarrays has not been realized. For
most published microarray studies, which may comprise
thousands of gene measurements across tens or hundreds
of cancer specimens, the authors have presented one inter-
pretation of their data and have reported on only a subset of
genes that demonstrate their particular hypothesis. The com-
plete microarray datasets are sometimes made available as
supplementary data, but even if that is the case, the datasets
often sit as cryptic text files, stored and processed in an
unsystematic manner, and thus only useful to those with
computational expertise. Although standards have now been
set for recording and exchanging microarray data [31], and
authors have been urged to provide their complete datasets
upon publication [32], the full potential of cancer microarray
data will only be reached when it is unified, logically ana-
lyzed, and made easily accessible to the cancer research
community.
Here we describe our ongoing effort to systematically
curate, analyze, and make available all public cancer micro-
array data via a web-based database and data-mining plat-
form, designated ONCOMINE (www.oncomine.org). Our
effort also includes centralizing gene annotation data from
various genome resources to facilitate rapid interpretation
of a gene’s potential role in cancer. Furthermore, we
are integrating microarray data analysis with other resources
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including gene ontology annotations and a Therapeutic
Target Database. In this report, we describe microarray
data collection and analysis, and data retrieval and visual-
ization methods available at ONCOMINE, and demonstrate
the potential for important discoveries.
Data Collection and Analysis
As the goal of this ongoing effort is to compile, analyze, and
serve all public cancer microarray data, we identified all
potential studies by literature searching, focusing on those
that have generated gene expression profiles of human
cancer tissue samples. We retrieved the complete datasets
if available and, if not, we contacted the authors to request
for the dataset. As of May 1, 2003, we cataloged information
on 152 cancer microarray studies (catalog available at
ONCOMINE), of which 40 studies were available and com-
piled—in total, 37,901,459 gene measurements from 3,762
microarray experiments. We processed and normalized
each dataset independently by a single method (see Meth-
ods section) and mapped each microarray feature to
Unigene build 159.
Although many analytical methods have been applied to
microarray data, we chose differential expression analysis
using t-statistics as a measure of differential expression, and
false discovery rates [33] as a corrected measure of signif-
icance. To define potential differential expression analyses,
we reviewed the samples in each dataset. Thirty-four data-
sets had samples corresponding to both classes of at least
one comparison of interest including cancer versus respec-
tive normal tissue, high-grade (undifferentiated) cancer ver-
sus low-grade (differentiated cancer) cancer, poor outcome
(metastases, recurrence, or cancer-specific death) cancer
versus good outcome (long-term or recurrence-free survival)
cancer, metastatic cancer versus primary cancer, and can-
cer subtype 1 (e.g., estrogen receptor–positive) versus
subtype 2 (e.g., estrogen–receptor negative). We conducted
a total of 81 differential expression analyses, encompassing
939,117 gene/cancer hypotheses. The genes most dif-
ferentially expressed in these analyses can be explored at
ONCOMINE (see below).
GENE Module
Unifying cancer microarray data and then processing, nor-
malizing, and analyzing all datasets by a single method allow
for gene centric analysis. Typically, researchers use a single
microarray dataset to identify a set of genes that are associ-
ated with a particular cancer type or subtype. With ONCO-
MINE, users can now assess and visualize the differential
expression of a selected gene across all available datasets
and differential expression analyses. After searching for a
gene of interest, ONCOMINE lists all differential expression
analyses in which the gene was included, and allows the user
to select analyses of interest. For the selected analyses, the
statistical results are provided and linked to graphical repre-
sentations of the microarray data. To illustrate the value of
gene centric analysis with ONCOMINE, we performed a
search for ERBB2 (i.e., HER2/neu), an oncogene known to
be amplified in a subset of breast tumors and targeted by the
antibody therapeutic, Herceptin [34]. We first looked at the
expression of ERBB2 in breast cancer as per the study of
Sorlie et al. [21]. We found that, as expected, ERBB2 is highly
overexpressed in a fraction of breast cancer samples relative
to normal breast samples (P = .057; Figure 1A). Next, we
looked at ERBB2 expression in all ‘‘cancer versus normal’’
analyses. Interestingly, ERBB2 was significantly overex-
pressed in diffuse large B-cell lymphoma (DLBCL) relative to
normal blood B-cells (P = 1.2e6), in non small cell lung
Figure 1. ERBB2 (Her2/neu) gene centric expression analysis as revealed by
ONCOMINE. (A) ERBB2 is overexpressed in a subset of breast cancers
relative to normal breast tissue (P = .0567). (B) ERBB2 is significantly
overexpressed in DLBCL relative to normal blood B-cells (P = 1.2e6), in
non small cell lung cancer relative to normal lung (P = 1.1e5), and in ovarian
carcinoma relative to normal ovary (P = 1.0e5), but not in hepatocellular
carcinoma or prostate cancer relative to their respective normal tissue. Y-axis
units are normalized expression values (standard deviations above or below
the median per array). The number of samples in each class is given in
parentheses. Adenoca. indicates adenocarcinoma; Ca. indicates carcinoma;
DLBCL indicates diffuse large B-cell lymphoma.
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cancer (NSCLC) relative to normal lung (P = 1.7e5 and
P = 1.1e5), and in ovarian carcinoma relative to normal
ovary (P = 1.0e5), but not in the majority of other cancer
types. Figure 1B depicts these analyses, along with selected
others that were not significant, as a multidataset box plot for
ERBB2. It is notable that the associations of Her2/neu with
NSCLC and ovarian cancer as revealed byONCOMINE have
been documented by other independent studies [35], and
clinical trials of Herceptin use for NSCLC are underway [36].
STUDY Module
The STUDY module provides a standard gene expression
color map to visualize genes most differentially expressed in
a selected analysis. Many of the differential expression anal-
yses are analogous to those performed in the original pub-
lications; however, withONCOMINE, they are centralized and
apply a single, robust statistical method. Furthermore, some
analyses available at ONCOMINE were not performed in
the original publications, thus increasing the value of these
microarray datasets. For example, Ramaswamy et al. pub-
lished a report on multicancer type classification highlighting
a focused gene set that can accurately classify tumor types of
different origin [16]. Because the dataset also included re-
spective normal tissue samples for many of the cancer types,
we performed multiple ‘‘cancer versus normal’’ differential
expression analyses, including pancreatic cancer versus nor-
mal pancreas—a hypothesis that was not testable from any
of the other available datasets. A final point about the STUDY
module: direct links are provided to theGENEmodule, so that
if the gene of interest is identified by exploring a differential
expression analysis, the user can quickly evaluate the gene’s
expression in other differential expression analyses (as dem-
onstrated below with prostasin).
Gene Ontology Integration
The focus of many cancer microarray studies is to identify
potential therapeutic targets or diagnostic markers. Genes
are usually considered as potential targets or markers if they
are highly overexpressed in a particular cancer, and their
molecular function or localization suggests that they might
be amenable to pharmacologic inhibition or detection in
serum or tissue. To provide a platform for the discovery of
potential targets or markers that are overexpressed in can-
cer, we annotated genes with relevant gene ontology
descriptors. Three ontology categories were created by
combining gene ontology annotations from GO ontology
consortium [37]: 1) membrane-bound, which could be tar-
geted by antibody therapies; 2) kinase, which could be
inhibited by small molecule kinase inhibitors; and 3) secret-
ed, which could serve as serum biomarkers. Significantly
overexpressed genes from each ontology category were
present in nearly all analyses. The genes in a particular
ontology category (e.g., membrane) that are most differen-
tially expressed in a specific analysis (e.g., lung adenocar-
cinoma versus normal lung) can be explored atONCOMINE.
Furthermore, specific GO annotations (e.g., DNA binding)
can also be used to filter differential expression analyses.
To demonstrate the utility of this approach, we will high-
light an analysis using ONCOMINE to identify serum bio-
markers for ovarian cancer. Ovarian cancer is in particular
need of improved serum biomarkers to aid in early detection
as it often presents late in the course of disease when
treatment options are limited. Recently, a study was pub-
lished suggesting prostasin as a potential serum biomarker
for ovarian cancer [28]. The authors profiled a small number
of ovarian cancer cell lines and found that prostasin was
overexpressed relative to normal ovary cell lines and then
used enzyme-linked immunosorbent assay to show that
prostasin protein is found at high levels in the serum of
ovarian cancer patients. Using the ‘‘secreted’’ filter inONCO-
MINE, we looked for genes overexpressed in ovarian cancer
based on a study by Welsh et al. [23], which had profiled 27
primary ovarian carcinomas. This search independently con-
firmed prostasin as one of the most highly overexpressed
geneswith a secreted annotation in ovarian cancer (Figure 2).
Had this resource been available to the authors of the
prostasin study [28], they could have avoided their micro-
array analysis of cell lines moving straight from ONCOMINE
to validation studies. Of note, genes encoding five other
secreted proteins were found to be more significantly over-
expressed than prostasin (LIF, SPINT2, LGALS3BP, LYZ,
and ECGF1), suggesting that more accurate biomarkers may
exist. A gene centric analysis of prostasin revealed that this
gene is also highly expressed in prostate cancer, as defined
by two independent datasets, and a subset of lung cancers,
suggesting a broadened role for this marker.
Known Therapeutic Target Integration
Based on the hypothesis that therapeutic agents are most
effective in cancer types in which their targets are highly
expressed (e.g., ERRB2 overexpression in breast cancer
leads to Herceptin susceptibility), we sought to provide a
platform to explore the expression of all known therapeutic
targets in cancer, even those that are targeted in diseases
other than cancer. We hypothesized that this platform may
lead to novel drug target–cancer type associations, suggest-
ing novel applications of therapeutic agents currently in use.
We compiled a set of 148 known drug targets and their
respective drugs by querying the Therapeutic Target Data-
base [38] and by automated PubMed searches (see Meth-
ods section). Sixty-five of these targets were found to be
significantly overexpressed in at least one differential ex-
pression analysis (data not shown).
Within the STUDY module, the user can apply the ther-
apeutic target filter to identify the targets most overex-
pressed in a particular differential expression analysis. For
example, we found that PTGS2, otherwise known as COX-2,
is the most significant overexpressed drug target in bladder
cancer relative to normal bladder tissue (Q = 3.1e15;
Figure 3A). COX-2 is the key enzyme in prostaglandin
biosynthesis and is targeted by nonsteroidal anti-inflamma-
tory medications such as aspirin. Unknown to us, COX-2 had
previously been shown to be overexpressed in bladder
cancer, and a COX-2 inhibitor, Celcoxib, was shown to inhibit
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bladder tumor formation in rats [39] and is currently in phase
III clinical trials for the prevention of bladder cancer in
humans [40]. Although this association was previously
made, our coincidental finding supports the value of this
approach.
The majority of hypotheses generated by this approach
remain to be explored. For example, effective treatment
strategies are desperately needed for pancreatic cancer,
as current treatments have limited efficacy with survival rates
less than 5% [41]. By applying the drug target filter, we found
that ABL1 (Abl tyrosine kinase) is the most significant over-
expressed drug target in pancreatic cancer relative to normal
pancreas (Q = 0.0097; Figure 3B). Abl kinase is targeted by
Gleevec, a small molecule inhibitor that has recently been
approved for first-line therapy in chronic myelogenous leu-
kemia [42]. Although the number of pancreatic samples in
which ABL1 was overexpressed is small (n = 8), the asso-
ciation is novel and worth exploring. If further studies con-
firmed ABL1 overexpression and demonstrated its role in
pancreatic carcinogenesis, perhaps Gleevec could be useful
in its management. A gene centric analysis of ABL1 further
revealed that it is overexpressed in glioblastoma (P = .0012)
and medulloblastoma (P = .0005).
ONCOMINE Extras and Future Directions
To facilitate the rapid interpretation of a gene’s potential
role in cancer, ONCOMINE provides a centralized gene
annotation resource, integrating information from other
bioinformatics resources including Swiss-Prot, LocusLink
[43], andUnigene, and providing direct links to HumanProtein
Reference Database (HPRD) [44] and SOURCE [45], and
the pathway resources Kyoto Encyclopedia of Genes and
Genomes (KEGG) [46] and Biocarta. An online tutorial is
provided at the ONCOMINE website to demonstrate its func-
tionality through a series of sample analyses. Future work will
include the collection of additionalmicroarray datasets as they
become available, increased integration with other genome
resources, and correlation-based analysis. ONCOMINE also
serves as a platform to explore the ‘‘metasignatures’’ identi-
fied from the cancer microarray compendium, as described in
our companion report (Submitted for publication).
In summary, ONCOMINE is a powerful platform for bio-
informatic discovery that brings cancer microarray data and
analysis capabilities to the fingertips of the cancer research
community. We hope that this work and the continued
support and development of ONCOMINE will stimulate fur-
ther research and maximum access to and hypothesis
generation from cancer microarray data, ultimately leading
to the improved understanding of cancer and the develop-
ment of novel diagnostic and therapeutic strategies.
Methods
Data Collection, Processing, and Storage
Microarray datasets were downloaded from public web-
sites or provided by the authors upon request. The web
Figure 3. Therapeutic targets overexpressed in cancer as revealed by
ONCOMINE. (A) PTGS2 (COX-2) is significantly overexpressed in bladder
cancer relative to normal bladder samples (Q = 3.1e15), confirming
previous work that COX-2 is a potential target for bladder cancer. (B) ABL1 is
significantly overexpressed in pancreatic cancer relative to normal pancreas
samples (Q = 0.0097), suggesting that the Abl tyrosine kinase inhibitor,
Gleevec, should be investigated for use. The number of samples in each
class is given in parentheses.
Figure 2. Genes encoding secreted proteins most significantly overex-
pressed in ovarian carcinoma relative to normal ovary samples as revealed
by ONCOMINE. PRSS8, the sixth most significant gene, was previously
shown to be an accurate serum biomarker for ovarian carcinoma [28]. Red
signifies overexpressed relative to the mean normal value, black equally
expressed, and green underexpressed. The number of samples in each class
is given in parentheses.
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addresses to download particular datasets are listed at
ONCOMINE (www.oncomine.org). All data that were avail-
able from the authors were included in processing and
analysis, except that negative values were not included. All
data were log-transformed, median centered per array, and
standard deviation normalized to one per array. Studies were
named by the following convention: FirstAuthor_TissueTy-
peProfiled (e.g., Dhanasekaran_Prostate). To facilitate mul-
tistudy analysis, microarray features were mapped to
Unigene Build 159. Data were stored in an Oracle 8.1
relational database.
Data Analysis
For each of the 40 microarray studies present in the
database, we reviewed the samples profiled. Thirty-four
studies had at least four samples corresponding to both
classes of one analysis of interest and were further analyzed.
Analyses of interest included cancer versus respective
normal tissue, high-grade (undifferentiated) cancer versus
low-grade (differentiated cancer) cancer, poor outcome (me-
tastases, recurrence, or cancer-specific death) cancer ver-
sus good outcome (long-term or recurrence-free survival)
cancer, primary cancer versus metastatic disease, and sub-
type 1 versus subtype 2. Following the assignment of sam-
ples to classes, each gene was assessed for differential
expression with t-statistics using Total Access Statistics
2002 (FMS Inc., Vienna, VA). t-Tests were conducted
both as two-sided for differential expression analysis and
one-sided for specific overexpression analysis. For the pur-
pose of whole study analysis, P values were corrected for
multiple comparisons by the method of false discovery rates.
Corrected P values are designated as Q values [33], where
Q = P* n / i (n = total number of genes; i = sorted rank of
P value).
Drug Target
Drug targets were defined by two methods. First, the
Therapeutic Target Database [38] was queried for all targets
that had a defined antagonist, inhibitor, or antibody. One
hundred nine unique drug targets were identified. The targets
were mapped to Unigene build 159 using gene names,
symbols, and aliases as provided by SOURCE [45]. Second,
all drug names present in the National Cancer Institute (NCI)
clinical trials database (http://www.nci.nih.gov/clinicaltrials/)
were subjected to automated PubMed searches, identifying
articles with the drug name and the word ‘‘inhibitor’’ or
‘‘antibody’’ in the title. This list of titles was manually investi-
gated for drugs and their specific targets (e.g., rituximab,
CD20). Fifty-three unique targets were identified by this
method. In total, 148 unique gene targets with specific drug
inhibitors or antibodies were identified.
Gene Ontology
GO gene ontology [37] annotations linked to Unigene
Cluster IDs were downloaded from SOURCE [45]. Three
ontology categories were created by combining multiple
annotations. The following annotations were part of the
membrane-bound category: cell adhesion receptor, G-pro-
tein coupled receptor, plasma membrane, peripheral plas-
ma membrane protein, transmembrane receptor, and
transmembrane receptor protein tyrosine kinase. The fol-
lowing were in the kinase category: 1-phosphatidylinositol
3-kinase, cyclin-dependent protein kinase, diacylglycerol ki-
nase, guanylate kinase, mitogen-activated protein (MAP)
kinase, MAP kinase kinase, MAP kinase kinase kinase,
nonmembrane-spanning protein tyrosine kinase, protein
kinase, protein kinase C, protein serine/threonine kinase,
protein tyrosine kinase, receptor signaling protein tyrosine
kinase, transmembrane receptor protein serine/threonine
kinase, and transmembrane receptor protein tyrosine ki-
nase. Lastly, the following annotations were part of the
secreted category: extracellular, extracellular matrix, and
extracellular space.
ONCOMINE
ONCOMINE was developed using three-tier architecture.
The back end consists of an Oracle 8i database for storing
microarray data and statistics, and a series of key-indexed
flat files for various biological databases. The middle tier,
which handles application logic and core functionality, was
developed with Python (www.python.org). The front–end
client was implemented using ZOPE (www.zope.org).
ONCOMINE is available at www.oncomine.org.
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